Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
A new weight loss drug has been approved that promises to be the most effective medication yet. How is Zepbound, the weekly injectable drug that’s expected to be available shortly after Thanksgiving, different from other weight loss medications? Zepbound, from drugmaker Eli Lilly, belongs to a new class of medications, called GLP-1 agonists, that have skyrocketed in popularity in the U.S. in recent years. Novo Nordisk's Ozempic and Wegovy and Lilly’s Mounjaro are the same type of drugs.
Wegovy is approved for people 12 and older. On Zepbound’s label, the FDA notes that the safety and effectiveness of Zepbound have not yet been established in teens or adolescents. McGowan stressed that both medications are highly effective. When deciding between Zepbound and Wegovy, he said patients should consider two factors: insurance coverage and their individual response to each treatment.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
FDA approves new obesity drug from Eli Lilly named ZepboundThe decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
Read more »
FDA approves a new weight loss drug, Zepbound from Eli LillyThe medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
Read more »
FDA approves new version of diabetes drug Mounjaro for weight lossThe U.S. Food and Drug Administration approved Eli Lilly’s Zepbound, or tirzepatide.
Read more »
Eli Lilly weight loss drug Zepbound approved by the FDADiabetes Drug Leads To, Significant Weight Loss in Those With Obesity, Study Finds. Researchers with Yale University recently published the results of their study in the 'New England Journal of Medicine.'. The diabetes drug tirzepatide was the focus of the study, which also included calorie restriction and 150 minutes of weekly exercise.
Read more »
Eli Lilly's Obesity Drug Gets FDA ApprovalThe drug will be marketed as an obesity treatment under the name Zepbound.
Read more »